Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
F1000Research|December 20, 2016
Recent advances in the medical treatment of breast cancerDaniel A VorobiofClinical Lung Cancer|April 14, 2009
Malignant pleural mesothelioma: medical treatment updateDaniel A Vorobiof, Keorapetse MafafoCurrent Treatment Options in Oncology|September 3, 2011
Bone targeted therapies in early breast cancerKeo Tabane, Daniel A VorobiofLung Cancer (Amsterdam, Netherlands)|July 21, 2004
Asbestos and mesothelioma in South AfricaRaymond P Abratt, Daniel A Vorobiof, Neil WhiteMelanoma Research|April 12, 2003
Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatmentDaniel A Vorobiof, Bernardo L Rapoport, Rabia Mahomed, et al.The Breast Journal|May 20, 2003
Primary osteosarcoma of the breast: a case reportGabriel Vorobiof, Gangaram Hariparsad, Woolf Freinkel, et al.Journal of Global Oncology|November 3, 2017
Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access ProgramBernardo L Rapoport, Daniel A Vorobiof, Lydia M Dreosti, et al.Lung Cancer Management|August 11, 2020
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancerBernardo L Rapoport, Annette J Theron, Daniel A Vorobiof, et al.Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.Pageof 2